Biosimilar therapy for breast cancer, zoledronic acid for bone metastases, the future of Obamacare under Donald Trump, and more

Editors’ Summary by Phil B. Fontanarosa, MD, MBA, Executive Editor of JAMA, the Journal of the American Medical Association, for the January 3, 2017 issue